iNtODEWORLD | Inside Intron
16537
page,page-id-16537,page-template,page-template-full_width,page-template-full_width-php,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

high-hemoglobin-count-good-1.1-800x800

iNtRON Biotechnology and Estech Pharma today announced that they have entered into the collaboration agreement on eHeme (engineered Heme) technology development. According to iNtRON Bio, two companies will make an investment together in the bio and chemical production of eHeme based on the iNtRON Bio’s relevant patents....

사장님 IR 발표사진

iNtRON Biotechnology held the corporate presentation for private and institutional investors on February 19, 2019. The purpose of the corporate presentation was to increase shareholders’ understanding about the company and investment value. During the corporate presentation, Seong Jun Yoon, CEO & Founder, made a presentation regarding...

b6ead0eba6bcabf732e08c147a5ccb48_1542671043_8411

Roivant plans to initiate Phase 2 clinical trial in 2019 Agreement includes option to in-license additional anti-Gr(+) programs   Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of...

orphandrug-1027

iNtRON Biotechnology has announced that N-Rephasin BAL200 for the treatment of anthrax infection has been received Orphan Drug Designation (ODD) from the US Food and Drug Administration (US FDA). Orphan Drug Designation is a program of FDA to support for the new drug development of rare...

3

On June 22, 2018, The 6th Korea Bacteriophage Research Society meeting was held at the iNtRON Bio’s conference room. 40 prominent bacteriophage researchers and related industry specialists have  participated in the meeting, and Professor Yong of Yonsei University, Professor Bae of Seoul National University, and Research...

KakaoTalk_20180523_095641087

To Focus on Investor Relations and Global Business Development As iNtRON Biotechnology (hereafter “iNtRON”) has grown up steadily, iNtRON has opened a new Seoul Office in the center of Seoul with great accessibility to focus on global business and investor relations. iNtRON is developing novel...

iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.
PGlmcmFtZSB3aWR0aD0iNzAwIiBoZWlnaHQ9IjM5NCIgc3JjPSJodHRwczovL3d3dy55b3V0dWJlLmNvbS9lbWJlZC81UDMxdTh6emF6az9yZWw9MCIgZnJhbWVib3JkZXI9IjAiIGFsbG93PSJhdXRvcGxheTsgZW5jcnlwdGVkLW1lZGlhIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+